Equities

TScan Therapeutics Inc

TCRX:NMQ

TScan Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.86
  • Today's Change-0.540 / -6.43%
  • Shares traded44.72k
  • 1 Year change+190.04%
  • Beta--
Data delayed at least 15 minutes, as of Jun 17 2024 17:08 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.

  • Revenue in USD (TTM)14.81m
  • Net income in USD-96.80m
  • Incorporated2018
  • Employees161.00
  • Location
    TScan Therapeutics Inc880 Winter StreetWALTHAM 02451United StatesUSA
  • Phone+1 (857) 399-9500
  • Fax+1 (302) 531-3150
  • Websitehttps://www.tscan.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ALX Oncology Holdings Inc0.00-166.20m419.41m74.00--2.46-----3.71-3.710.003.270.00----0.00-67.73-34.34-76.12-36.47-------7,238.76----0.067-------30.23--14.30--
AC Immune SA16.63m-61.32m422.58m133.00--2.60--25.41-0.6877-0.68770.18711.640.088--61.04125,026.10-32.45-18.25-35.04-19.52-----368.77-148.29----0.0225--276.1415.5223.35---15.49--
Nkarta Inc0.00-116.20m423.51m150.00--0.894-----2.35-2.350.006.720.00----0.00-22.45-32.39-23.55-34.05-------372,519.20----0.00-------3.22--106.05--
IGM Biosciences Inc2.11m-236.92m429.69m216.00--2.66--204.13-4.31-4.310.03752.740.005----9,397.32-56.49-44.66-62.57-48.20-----11,255.25-23,668.96----0.00--99.25---11.45--73.48--
Altimmune Inc410.00k-92.77m433.21m59.00--2.50--1,056.62-1.59-1.590.0072.440.0022--1.476,949.15-49.42-39.62-53.14-42.58-----22,626.10-1,811.89----0.00--726.47-47.15-4.41---45.92--
Tourmaline Bio Inc0.00-32.94m434.96m44.00--1.23-----5.35-5.350.0013.810.00----0.00-12.39---12.75--------------0.00------42.99------
Exscientia PLC (ADR)24.87m-164.01m436.19m483.00--1.52--17.54-1.30-1.300.19683.320.0364--34.9851,484.14-24.02---27.31---34.40---659.56------0.0556---26.24---22.94------
Tscan Therapeutics Inc14.81m-96.80m444.05m161.00--3.27--29.98-1.28-1.280.17842.570.0715----96,181.82-46.72---52.48-------653.50------0.1974--55.52---34.73------
Avid Bioservices Inc136.74m-18.26m449.75m365.00--2.50--3.29-0.2888-0.28882.172.840.3023.184.89374,616.40-4.0310.70-6.1315.187.4722.72-13.3525.860.3097-4.470.45480.0024.8122.72-99.80--82.98--
Absci Corp5.35m-109.19m450.07m155.00--1.87--84.17-1.17-1.170.05692.120.0187--7.8234,496.77-38.26---42.14-------2,042.01-----107.740.0298---0.5046---5.40------
Alector Inc96.41m-120.61m451.08m244.00--2.52--4.68-1.39-1.391.121.860.1393----395,106.60-17.43-20.00-21.55-23.81-----125.11-124.07----0.00---27.3628.522.19--4.79--
Verve Therapeutics Inc16.05m-196.83m455.09m255.00--0.7792--28.36-2.87-2.870.23096.960.0235--4.4862,937.25-28.80---30.24-------1,226.43------0.00--505.77---27.12------
Compass Pathways PLC (ADR)0.00-129.44m455.42m186.00--1.76-----2.37-2.370.003.790.00----0.00-53.68-40.85-57.32-44.48-----------43.340.1009-------29.46---12.68--
Adaptive Biotechnologies Corp174.50m-215.06m461.26m709.00--1.68--2.64-1.48-1.481.201.870.24724.524.78246,124.10-30.48-19.69-34.73-22.0657.0667.18-123.29-122.274.35--0.3238---8.1125.06-12.52--11.11--
Voyager Therapeutics Inc119.04m-3.04m462.89m162.00--1.36304.933.89-0.1812-0.18122.446.280.2954--8.27734,839.50-0.75540.6378-0.85340.8203-----2.561.30----0.000.00511.16101.01385.14---5.43--
Fulcrum Therapeutics Inc2.51m-99.43m463.04m76.00--2.17--184.48-1.61-1.610.04063.440.0091--2.1433,026.32-35.91-50.55-37.62-55.91-----3,961.20-1,189.10----0.00---55.77--11.41---43.70--
Data as of Jun 17 2024. Currency figures normalised to TScan Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

58.39%Per cent of shares held by top holders
HolderShares% Held
Lynx1 Capital Management LPas of 19 Apr 20245.22m10.75%
EcoR1 Capital, LLCas of 31 Mar 20245.00m10.29%
Adage Capital Management LPas of 31 Mar 20243.90m8.03%
BVF Partners LPas of 31 Mar 20242.99m6.15%
Baker Bros. Advisors LPas of 19 Apr 20242.78m5.73%
Cormorant Asset Management LPas of 19 Apr 20242.50m5.15%
Propel Bio Management LLCas of 31 Mar 20242.09m4.30%
The Vanguard Group, Inc.as of 31 Mar 20241.79m3.69%
Simplify Asset Management, Inc.as of 31 Mar 20241.05m2.16%
BlackRock Advisors LLCas of 31 Mar 20241.05m2.15%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.